WO2001005945A3 - Packaging systems for human recombinant adenovirus to be used in gene therapy - Google Patents

Packaging systems for human recombinant adenovirus to be used in gene therapy Download PDF

Info

Publication number
WO2001005945A3
WO2001005945A3 PCT/EP2000/007074 EP0007074W WO0105945A3 WO 2001005945 A3 WO2001005945 A3 WO 2001005945A3 EP 0007074 W EP0007074 W EP 0007074W WO 0105945 A3 WO0105945 A3 WO 0105945A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenovirus
recombinant adenovirus
vector
recombinant
gene therapy
Prior art date
Application number
PCT/EP2000/007074
Other languages
French (fr)
Other versions
WO2001005945A2 (en
WO2001005945A9 (en
Inventor
Robert C Hoeben
Abraham Bout
Domenico Valerio
Der Eb Alex J Van
Govert Schouten
Frits J Fallaux
Original Assignee
Introgene Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgene Bv filed Critical Introgene Bv
Priority to CA002378061A priority Critical patent/CA2378061A1/en
Priority to EP00965872A priority patent/EP1196544A2/en
Priority to AU76469/00A priority patent/AU7646900A/en
Publication of WO2001005945A2 publication Critical patent/WO2001005945A2/en
Publication of WO2001005945A3 publication Critical patent/WO2001005945A3/en
Publication of WO2001005945A9 publication Critical patent/WO2001005945A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Abstract

The problem of replication competent adenovirus in virus production is solved in that we have developed packaging cells that have no overlapping sequences with a new basic vector and thus are suited for safe large scale production of recombinant adenoviruses one of the additional problems associated with the use of recombinant adenovirus vectors is the host-defense reaction against treatment with adenovirus. Another aspect of the invention involves screening recombinant adenovirus vector lots, especially those intended for clinical use, for the presence of adenovirus E1 sequences, as this will reveal replication competent adenovirus, as well as revertant E1 adenoviruses. It is also an aspect of the present invention to molecularly characterize the revertants that are generated in the newer helper/vector combinations.
PCT/EP2000/007074 1999-07-19 2000-07-19 Packaging systems for human recombinant adenovirus to be used in gene therapy WO2001005945A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002378061A CA2378061A1 (en) 1999-07-19 2000-07-19 Packaging systems for human recombinant adenovirus to be used in gene therapy
EP00965872A EP1196544A2 (en) 1999-07-19 2000-07-19 Packaging systems for human recombinant adenovirus to be used in gene therapy
AU76469/00A AU7646900A (en) 1999-07-19 2000-07-19 Packaging systems for human recombinant adenovirus to be used in gene therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/356,575 US6265212B1 (en) 1995-06-15 1999-07-19 Packaging systems for human recombinant adenovirus to be used in gene therapy
US09/356,575 1999-07-19

Publications (3)

Publication Number Publication Date
WO2001005945A2 WO2001005945A2 (en) 2001-01-25
WO2001005945A3 true WO2001005945A3 (en) 2001-08-09
WO2001005945A9 WO2001005945A9 (en) 2002-09-06

Family

ID=23402023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007074 WO2001005945A2 (en) 1999-07-19 2000-07-19 Packaging systems for human recombinant adenovirus to be used in gene therapy

Country Status (5)

Country Link
US (2) US6265212B1 (en)
EP (1) EP1196544A2 (en)
AU (1) AU7646900A (en)
CA (1) CA2378061A1 (en)
WO (1) WO2001005945A2 (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) * 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DK1445322T4 (en) * 1995-06-15 2012-09-03 Crucell Holland Bv Packaging systems for human recombinant adenovirus for use in gene therapy
US20020088014A1 (en) * 1996-05-31 2002-07-04 Xiangming Fang Minimal adenovirus mediated recombinant vaccine
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
CA2385538C (en) * 1999-09-17 2007-11-06 Tgt Laboratories, S.A. De C.V. Recombinant adenoviral vectors and their utilization in the treatment of various types of hepatic, renal and pulmonary fibrosis and hypertrophic scars
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
MXPA00011713A (en) * 2000-11-28 2002-05-31 Tgt Lab S A De C V Re-combining viral and non-viral vectors containing the human gene of the urokinase plasminogen activator and its benefit in the treatment of diverse types of hepatic, renal, pulmonary, pancreatic and cardiac fibrosis and hypertrophic scars.
EP1513956A2 (en) * 2002-06-07 2005-03-16 Novartis AG Assay to detect replication competent viruses
EP2258850B1 (en) 2002-12-17 2013-07-17 Crucell Holland B.V. Recominant viral-based malaria vaccins
JP4644656B2 (en) 2003-01-08 2011-03-02 エクソンモービル・ケミカル・パテンツ・インク Elastic product and manufacturing method thereof
US8067371B2 (en) * 2003-05-09 2011-11-29 The Trustees Of Columbia University In The City Of New York RAGE G82S-related methods and compositions for treating inflammatory disorders
ATE414144T1 (en) 2003-05-09 2008-11-15 Crucell Holland Bv CULTURES OF E1-IMMORALIZED CELLS AND METHOD FOR CULTIVATION THEM TO INCREASE THE PRODUCT YIELDS THEREOF
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
US7189561B2 (en) * 2004-09-21 2007-03-13 Advec, Inc. Production of adenovirus vectors with reduced levels of replication competent adenovirus contamination
EP1802699B1 (en) 2004-10-13 2011-07-27 ExxonMobil Chemical Patents Inc. Elastomeric reactor blend compositions
US7807593B2 (en) * 2005-10-26 2010-10-05 Dow Global Technologies Inc. Multi-layer, pre-stretched elastic articles
EP2132300B1 (en) * 2007-03-09 2011-01-12 Vectorlogics, Inc. Cells for adenovirus vector and protein production
US20090053959A1 (en) * 2007-08-21 2009-02-26 Sudhin Datta Soft and Elastic Nonwoven Polypropylene Compositions
US9017593B2 (en) 2009-06-16 2015-04-28 Exxonmobil Chemical Patents Inc. Composite materials comprising propylene-based polymer blend coatings
US20100316820A1 (en) * 2009-06-16 2010-12-16 Rainer Kolb Composite Materials Comprising Propylene-Based Polymer Blend Coatings
US20110059277A1 (en) * 2009-09-04 2011-03-10 Rainer Kolb Elastomeric Surface Coatings for Plastic Articles
US20100316808A1 (en) * 2009-06-16 2010-12-16 Gregory Keith Hall Polyolefin Compositions for Coating Applications
US9005739B2 (en) * 2009-07-23 2015-04-14 Exxonmobil Chemical Patents Inc. Laminated articles and their production
WO2011011124A1 (en) 2009-07-23 2011-01-27 Exxonmobil Chemical Patents Inc. Polypropylene-based elastomer coating compositions
US9879160B2 (en) 2009-10-29 2018-01-30 Exxonmobil Chemical Patents Inc. Pressure-sensitive hot melt adhesive compositions
CN102741430B (en) 2009-12-01 2016-07-13 牛津楠路珀尔科技有限公司 Biochemical analyzer, for first module carrying out biochemical analysis and associated method
SG188465A1 (en) 2010-10-15 2013-05-31 Exxonmobil Chem Patents Inc Polypropylene-based adhesive compositions
ES2623259T3 (en) 2011-12-08 2017-07-10 Virovek, Inc. Vectors that house toxic genes, methods and uses thereof
EP3390056B1 (en) 2015-12-16 2020-11-18 ExxonMobil Chemical Patents Inc. Low crystalline polymer compositions
CA3018952C (en) 2016-03-31 2023-06-27 Exxonmobil Chemical Patents Inc. Low crystalline polymer compositions prepared in a dual reactor
CN110832072B (en) 2017-04-21 2023-11-07 真基因太科公司 Cell line for producing non-replicating adenovirus and method for preparing said cell line

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034671A1 (en) * 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
WO1996014061A1 (en) * 1994-11-03 1996-05-17 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
WO1997021826A2 (en) * 1995-12-14 1997-06-19 Genvec, Inc. Complementary adenoviral vector systems and cell lines
WO1998054345A1 (en) * 1997-05-30 1998-12-03 Baxter International Inc. Mini-adenoviral vector
EP0955373A2 (en) * 1998-04-24 1999-11-10 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5994128A (en) * 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4727028A (en) 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US4740463A (en) 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
US5378618A (en) 1988-04-15 1995-01-03 E. I. Du Pont De Nemours And Company Vitro headful packaging system for cloning DNA fragments as large as 95kb
US5585362A (en) * 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5518913A (en) 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
CA2053187A1 (en) 1991-10-10 1993-04-11 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
WO1994023582A1 (en) 1993-04-08 1994-10-27 Genetic Therapy, Inc. Adenoviral vectors including dna encoding lung surfactant protein
FR2705361B1 (en) 1993-05-18 1995-08-04 Centre Nat Rech Scient Viral vectors and use in gene therapy.
FR2705686B1 (en) 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
US5919676A (en) 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
FR2707664B1 (en) 1993-07-13 1995-09-29 Centre Nat Rech Scient Viral vectors and use in gene therapy.
CZ287157B6 (en) 1993-07-13 2000-10-11 Rhone Poulenc Rorer Sa Defective recombinant adenovirus and pharmaceutical preparation in which said adenovirus is comprised
CA2117668C (en) 1994-03-09 2005-08-09 Izumu Saito Recombinant adenovirus and process for producing the same
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ATE246252T1 (en) 1994-08-16 2003-08-15 Crucell Holland Bv ADENOVIRUS-DERIVED RECOMBINANT VECTORS FOR GENE THERAPY
WO1996016676A1 (en) 1994-11-28 1996-06-06 Genetic Therapy, Inc. Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors
WO1996018418A1 (en) 1994-12-12 1996-06-20 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5707618A (en) 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
AU5551996A (en) 1995-04-17 1996-11-07 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
US6265212B1 (en) * 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2735789B1 (en) 1995-06-23 1997-07-25 Centre Nat Rech Scient RECOMBINANT ADENOVIRUSES, THEIR USE FOR PREPARING AVA, COMPLEMENTARY CELL LINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
FR2737222B1 (en) 1995-07-24 1997-10-17 Transgene Sa NEW VIRAL AND LINEAR VECTORS FOR GENE THERAPY
FR2737501B1 (en) 1995-07-31 1997-10-24 Transgene Sa NOVEL AUXILIARY VIRUSES FOR THE PREPARATION OF RECOMBINANT VIRAL VECTORS
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995034671A1 (en) * 1994-06-10 1995-12-21 Genvec, Inc. Complementary adenoviral vector systems and cell lines
WO1996014061A1 (en) * 1994-11-03 1996-05-17 Cell Genesys, Inc. Novel adenoviral vectors, packaging cell lines, recombinant adenoviruses and methods
US5994128A (en) * 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1997021826A2 (en) * 1995-12-14 1997-06-19 Genvec, Inc. Complementary adenoviral vector systems and cell lines
WO1998054345A1 (en) * 1997-05-30 1998-12-03 Baxter International Inc. Mini-adenoviral vector
EP0955373A2 (en) * 1998-04-24 1999-11-10 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ENGELHARDT J F ET AL: "ABLATION OF E2A IN RECOMBINANT ADENOVIRUSES IMPROVES TRANSGENE PERSISTENCE AND DECREASES INFLAMMATORY RESPONSE IN MOUSE LIVER", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 91, 1 June 1994 (1994-06-01), pages 6196 - 6200, XP000673290, ISSN: 0027-8424 *
FALLAUX F ET AL: "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses", HUMAN GENE THERAPY,XX,XX, vol. 9, no. 9, 1 September 1998 (1998-09-01), pages 1909 - 1917, XP002111070, ISSN: 1043-0342 *
GOLDMAN M J ET AL: "TRANSFER OF THE CFTR GENE TO THE LUNG OF NONHUMAN PRIMATES WITH E1-DELETED, E2A-DEFECTIVE RECOMBINANT ADENOVIRUSES: A PRECLINICAL TOXICOLOGY STUDY", HUMAN GENE THERAPY,XX,XX, vol. 6, no. 7, 1 July 1995 (1995-07-01), pages 839 - 851, XP000671586, ISSN: 1043-0342 *
YANG Y ET AL: "INACTIVATION OF E2A IN RECOMBINANT ADENOVIRUSES IMPROVES THE PROSPECT FOR GENE THERAPY IN CYSTIC FIBROSIS", NATURE GENETICS,US,NEW YORK, NY, vol. 7, no. 3, 1 July 1994 (1994-07-01), pages 362 - 369, XP000573932, ISSN: 1061-4036 *
ZHOU H ET AL: "DEVELOPMENT OF A COMPLEMENTING CELL LINE AND A SYSTEM FOR CONSTRUCTION OF ADENOVIRUS VECTORS WITH E1 AND E2A DELETED", JOURNAL OF VIROLOGY,US,THE AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 70, no. 10, 1 October 1996 (1996-10-01), pages 7030 - 7038, XP002059962, ISSN: 0022-538X *

Also Published As

Publication number Publication date
US6692966B2 (en) 2004-02-17
WO2001005945A2 (en) 2001-01-25
CA2378061A1 (en) 2001-01-25
EP1196544A2 (en) 2002-04-17
US20020187553A1 (en) 2002-12-12
AU7646900A (en) 2001-02-05
WO2001005945A9 (en) 2002-09-06
US6265212B1 (en) 2001-07-24

Similar Documents

Publication Publication Date Title
WO2001005945A3 (en) Packaging systems for human recombinant adenovirus to be used in gene therapy
HUP0400660A2 (en) Use of biologically active hiv-1-tat, fragments or derivatives thereof, to target and/or to active antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases
WO2004027033A3 (en) Lentiviral vector-mediated gene transfer and uses thereof
NO921848D0 (en) SILICO SOLAS, PROCEDURE FOR PREPARING THEREOF, AND USING THE SOLES.
DK1445322T3 (en) Packaging systems for human recombinant adenovirus for use in gene therapy
WO1999054461A3 (en) Human nucleic acid sequences of endometrium tumour tissue
BR9710452A (en) Anïïlogos of exendin processes for its preparation and medicines containing the same
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
NO20010277D0 (en) Benzocycloheptenes, process for their preparation, pharmaceutical preparations containing them, and their use in the manufacture of medicaments
BR9808509A (en) Compositions and methods for the treatment and diagnosis of breast cancer
EP1343532A4 (en) Lentiviral vector-mediated gene transfer and uses thereof
ATE371031T1 (en) HERPES SIMPLEX VIRUS EXPRESSING THE INTERLEUKIN-12 GENE AND ITS USE IN THE TREATMENT OF CANCER
DK0843731T3 (en) Gene therapy adenovirus vectors
IT1188921B (en) IMPROVEMENT IN TITANIUM CATALYSTS FOR THE POLYMERIZATION AND COPOLYMERIZATION OF ALCHENI-1 AND PROCEDURE FOR THEIR PREPARATION
WO1999054447A3 (en) Human nucleic acid sequences of bladder tumour tissue
NO934160L (en) 2-Amino-1,2,3,4-tetrahydronaphthalene derivatives with cardiovascular activity, methods of preparation thereof, and pharmaceutical preparations containing such
WO2001044280A3 (en) Methods and compositions for the manufacture of replication incompetent adenovirus
ATE473763T1 (en) REPLICATING ADENOVIRUS VECTORS
NO884770D0 (en) PROCEDURE FOR THE PREPARATION OF DI-T-BUTYL PHENOLES AND INTERMEDIATE PRODUCTS FOR USE BY THIS.
WO1998035045A3 (en) Leishmania antigens for use in the therapy and diagnosis of leishmaniasis
ATE103980T1 (en) VACCINE CONTAINING THE F-PROTEIN FROM THE AIDS VIRUS.
IT8048314A0 (en) IMPROVEMENT IN TITANIUM CATALYST FOR THE POLYMERIZATION AND COPOLYMERIZATION OF ALkenes-1 AND PROCEDURE FOR THEIR PREPARATION
NO983947D0 (en) Use of 2- (3,4-dimethoxycinnamoyl) amine benzoic acid in the manufacture of a medicament for the treatment or prevention of restenosis
NO894638L (en) SILICONE PRODUCT FOR USE IN THE MANUFACTURE OF ORGANOSILANES AND CHLORESILANES AND PROCEDURES FOR THE MANUFACTURE OF SILICONE PRODUCT.
Elmer-DeWitt The future of drugs.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000965872

Country of ref document: EP

Ref document number: 76469/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 516682

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2378061

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2000965872

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

COP Corrected version of pamphlet

Free format text: PAGES 8/21-9/21, DRAWINGS, REPLACED BY NEW PAGES 8/21-9/21; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWW Wipo information: withdrawn in national office

Ref document number: 2000965872

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP